| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
57,793 |
53,358 |
$2.11M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
56,084 |
51,764 |
$1.73M |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
4,425 |
4,164 |
$627K |
| 64635 |
|
1,107 |
1,023 |
$313K |
| L0650 |
Lumbar-sacral orthosis, sagittal-coronal control, with rigid anterior and posterior frame/panel(s), posterior extends from sacrococcygeal junction to t-9 vertebra, lateral strength provided by rigid lateral frame/panel(s), produces intracavitary pressure to reduce load on intervertebral discs, includes straps, closures, may include padding, shoulder straps, pendulous abdomen design, prefabricated, off-the-shelf |
393 |
323 |
$214K |
| J3300 |
Injection, triamcinolone acetonide, preservative free, 1 mg |
1,497 |
1,251 |
$177K |
| 64493 |
|
1,562 |
1,258 |
$154K |
| 64636 |
|
1,261 |
992 |
$137K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
1,051 |
975 |
$100K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,119 |
2,001 |
$99K |
| 62323 |
|
711 |
651 |
$88K |
| 64494 |
|
1,646 |
1,232 |
$80K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
849 |
788 |
$70K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
918 |
862 |
$55K |
| 27096 |
|
260 |
227 |
$48K |
| 77002 |
|
1,519 |
1,299 |
$46K |
| 20610 |
|
1,007 |
856 |
$36K |
| 95886 |
|
442 |
337 |
$32K |
| 76942 |
|
612 |
518 |
$25K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,801 |
1,553 |
$14K |
| 64490 |
|
135 |
117 |
$13K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,418 |
2,186 |
$13K |
| 62370 |
|
235 |
205 |
$11K |
| 95913 |
|
57 |
53 |
$9K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
366 |
325 |
$7K |
| 64491 |
|
124 |
105 |
$6K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
754 |
675 |
$6K |
| 62321 |
|
43 |
41 |
$5K |
| 80305 |
|
514 |
470 |
$4K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
2,174 |
1,973 |
$4K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
40 |
37 |
$3K |
| 95912 |
|
17 |
15 |
$3K |
| 95910 |
|
18 |
15 |
$2K |
| 95911 |
|
16 |
14 |
$2K |
| 62368 |
|
71 |
53 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
184 |
177 |
$727.26 |
| 64450 |
|
21 |
14 |
$632.37 |
| 20553 |
|
13 |
12 |
$494.48 |
| 76000 |
|
12 |
12 |
$342.20 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
25 |
24 |
$287.80 |
| 62367 |
|
13 |
13 |
$75.79 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
13 |
12 |
$8.13 |